AFT Pharmaceuticals to raise $33.2 mln in IPO to fund R&D pipeline

AFT Pharmaceuticals to raise $33.2 mln in IPO to fund R&D pipeline
Nov. 27 (BusinessDesk) - AFT Pharmaceuticals, the Auckland-based company whose products include Maxigesic pain medication and Maxiclear PE nasal decongestant, plans to raise $33.2 million to fund a research and development pipeline over the next two to three years.   The Auckland-based company set the price of 11.9 million shares to be offered at $2.80 apiece, following an institutional bookbuild, valuing AFT at $269 million, it said in a statement. The IPO includes $30.2 million of new capital to fund growth at AFT with the ability to accep...